Skip to main content
Equibles
NPHC logo

NPHC · Nutra Pharma Corp · Metrics

Track NPHC — free

Use NPHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NPHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 19, 2026
Market Cap
$715,972
Shares
7.16B
Volume · Oct 19 928.01K Avg daily vol (3M) 327.42K

NPHC metrics

57 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$715,972

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
-66.7%
Price change (6M)
-50.0%
Price change (YTD)
+0.0%
Price change (1Y)
+0.0%
Trailing year
Price change (5Y)
-96.2%
52-week high
$0.00
52-week low
$0.00
Change from 52-week high
-90.0%
Change from 52-week low
+0.0%
Annualized volatility
583.6%
Annualized volatility (3M)
—
Beta
-2.3
RSI (14D)
40.3
Price vs SMA 50
-32.4%
Price vs SMA 200
-42.0%
Avg volume (3M)
299,310
Relative volume
0.0
Average dollar volume
$30

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
7.16B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
65.0×
reciprocal yield 1.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
4.5×
reciprocal yield 22.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-757.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
78.1%
Operating margin
-1,017.8%
Trailing 12 months
Net margin
-3,370.6%
Gross profit (TTM)
$125,669
Operating profit (TTM)
−$1.64M
Net income (TTM)
−$5.42M
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-59.2%
Year over year
Net income growth YoY
-1,168.5%
Revenue (TTM)
$160,815
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-78.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+20.9%
Revenue CAGR (5Y)
+37.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-870.3%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.80M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-68.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$9.73M
Latest balance sheet
Cash & equivalents
$12,181
Total assets
$622,863
Total debt
$12.57M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.05M
Capital expenditures (TTM)
$26,052
R&D (TTM)
$446
SG&A (TTM)
$1.47M
Stock compensation (TTM)
$39,833
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1119643 Visit website Investor relations